P Weidmann, D E Uehlinger, A Gerber. Show Affiliations »
Abstract
Mesh： See more » Adrenergic beta-Antagonists/adverse effectsAdrenergic beta-Antagonists/therapeutic useAngiotensin-Converting Enzyme InhibitorsAnimalsBenzothiadiazinesCalcium Channel Blockers/adverse effectsCalcium Channel Blockers/therapeutic useCholesterol/bloodCholesterol, HDL/bloodCholesterol, LDL/bloodCholesterol, VLDLCoronary Disease/etiologyDiuretics/adverse effectsDiuretics/therapeutic useDrug Therapy, CombinationEstrogens/physiologyFemaleHumansHyperlipoproteinemias/chemically inducedHypertension/bloodHypertension/complicationsHypertension/drug therapyKineticsLipoproteins/bloodLipoproteins, VLDL/bloodLiver/metabolismMaleMenopauseRiskSex FactorsSodium Chloride Symporter Inhibitors/adverse effectsSodium Chloride Symporter Inhibitors/therapeutic useSympatholytics/adverse effectsSympatholytics/therapeutic useTriglycerides/bloodVasodilator Agents/adverse effectsVasodilator Agents/therapeutic use
Substances： See more » Adrenergic beta-AntagonistsAngiotensin-Converting Enzyme InhibitorsBenzothiadiazinesCalcium Channel BlockersCholesterol, HDLCholesterol, LDLCholesterol, VLDLDiureticsEstrogensLipoproteinsLipoproteins, VLDLSodium Chloride Symporter InhibitorsSympatholyticsTriglyceridesVasodilator Agentsvery low density lipoprotein triglycerideCholesterol
Year: 1985 PMID： 2864373 DOI： 10.1097/00004872-198508000-00001
Source DB: PubMed Journal: J Hypertens ISSN： 0263-6352 Impact factor: 4.844